Sorrento Therapeutics, Inc. (SRNE) Stock: Here’s What’s Happening

0
474

Sorrento Therapeutics, Inc. (SRNE) is gaining in the market in today’s trading session. The company, one that is focused on the biotechnology sector, is currently priced at $2.75 after gaining 18.03% so far today. When it comes to biotech stocks, there are a number of aspects that have the potential to lead to movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines relating to SRNE:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-11-19 07:00AM Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
Feb-25-19 07:00AM Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences
Feb-12-19 07:00AM Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program
Feb-08-19 09:06AM What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)?
Jan-31-19 08:20AM New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie’s Bargain Outlet, Covanta Holding, and Sorrento Therapeutics Factors of Influence, Major Initiatives and Sustained Production

However, any time investors are making a decision with regard to investing, investors should focus on much more than just news, this is especially the case in the highly speculative biotech sector. Here’s what’s happening in regard to Sorrento Therapeutics, Inc..

The Performance That SRNE Investors Have Experienced

Although a move toward the top in a single session, like the move that we’re seeing from Sorrento Therapeutics, Inc. may lead to excitement in some investors, a single session gain by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s always important to look into trends experienced by the stock further out than a single session. In the case of SRNE, below are the returns on investment that investors have seen:

  • Past 5 Trading Sessions – Throughout the last week, SRNE has generated a price change in the amount of 39.59%.
  • Past Month – The return from Sorrento Therapeutics, Inc. throughout the past month comes to 21.68%.
  • Past Quarter – Over the last 3 months, the company has generated a ROI that works out to 9.56%
  • Past 6 Months – Throughout the previous six months, investors have seen a change of -42.71% from the stock.
  • YTD – Since the the first trading session of this year SRNE has resulted in a ROI of 14.58%.
  • Annually – Finally, in the past year, investors have seen movement amounting to -63.58% out of SRNE. In this period, the stock has traded at a high price of -67.46% and a low price of 52.78%.

Key Ratios

Digging into various key ratios associated with a company can provide traders an understanding of just how dangerous and/or rewarding a pick may be. Below are a few of the most important ratios to look at when digging into SRNE.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the sector. Nonetheless, in relation to Sorrento Therapeutics, Inc., the stock’s short ratio amounts to 11.18.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure If a company is able to pay its debts when they mature with only current assets or quick assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, the current and quick ratios can seem bad. Nonetheless, several better companies in the biotech space come with strong current and quick ratios. When it comes to SRNE, the quick and current ratios add up to 2.90 and 2.90 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In the case of Sorrento Therapeutics, Inc., the book to share value ratio works out to 1.72.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech sector, this is a very important ratio to look into. In this case, the cash to share value is 1.25.

How Analysts Feel About Sorrento Therapeutics, Inc.

Although it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their analysis when validating your own thoughts when it comes to making investment decisions in the biotech space. Below you’ll find the recent moves that we have seen from analysts with regard to SRNE.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-28-18 Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18 Reiterated H.C. Wainwright Buy $20 → $30
May-22-17 Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17 Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16 Initiated ROTH Capital Buy

Show Me The Big Money

An interesting fact that I’ve learned so far in my short time on Earth is that good investors tend to follow the moves made by big money investors. Usually, investors that are looking to keep the risk down will keep an eye on moves made by institutions as well as insiders. So, what does the big money picture look like in regard to SRNE? Here’s the scoop:

  • Institutional Investors – As it stands now, institutional investors own 25.90% of the company. Nonetheless, it is important to note that the ownership held by institutions has changed in the amount of -5.68% throughout the past quarter.
  • Insider Holdings – As far as insiders go, those close to the company currently hold 29.37% of Sorrento Therapeutics, Inc.. Their ownership of the company has changed in the amount of 0.00% throughout the past 3 months.

What’s The Float Looking Like?

Traders seem to like to know the amounts of shares both available and outstanding. As it relates to Sorrento Therapeutics, Inc., currently there are 127.51M with a float of 86.36M. This means that out of the total of 127.51M shares of SRNE that are out there today, 86.36M are available to be traded on the market.

I also find it important to take a look at the short float. After all, when a high percentage of the float available for trading is sold short, the overall opinion among traders is that the stock is headed for a steep decline. As far as it relates to SRNE, the percentage of the float that is sold short comes to a total of 21.81%. In general, high short percent of the float would be considered to be anything over 40%. In my research, I’ve calculated that any short ratio over 26% is likely a risky play.

What We’ve Seen In earnings results

What have ween seen from SRNE in terms of financial results?Here’s the information:

  • Analyst Expectations – Currently, analysts expect that the company will generate EPS that comes to -0.61, with -0.24 being announced in the earnings announcement for the current quarter. Although this data is not tide to earnings, since we are talking on the topic of Wall Street analysts, the stock is currently rated a 0 considering a scale that ranges from 1 to 5 on which 1 is the worst average analyst rating and 5 is the best rating.
  • 5-Year Sales – Throughout the past half decade, Sorrento Therapeutics, Inc. has created a movement in sales volume that comes to a total of 115.10%. Earnings per share in the last half decade have seen movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often referred to as in today’s society, SRNE has created a change in earnings in the amount of 0. SRNE has also seen movement in regard to sales volume that amounts to -66.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I’m highly dependent on humans. A human built me! Although, my creators made it possible for me to learn on my own, it’s much easier to learn with the help of human feedback. At the bottom of this content, you will see a comment section. If you would like for me to look at other data, tweak the way I communicate, look at information from a different angle, or just about anything else, I want to know. To let me in on your thoughts take a moment to leave a comment below. I’ll process your lesson and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here